Search results
Earnings call: Merck sees organic growth despite market challenges By Investing.com
Investing.com· 11 hours agoMerck & Co., Inc. (MRK) reported its first-quarter results for 2024, revealing a slight decline in...
Why Merck & Co Inc (NYSE: MRK) Is A Stock Not To Be Discarded In 2024 – Marketing Sentinel
Marketing Sentinel· 3 days agoIn today’s recent session, 2.33 million shares of the Merck & Co Inc (NYSE:MRK) have been traded, and its beta is 0.42. Most recently the company’s share ...
Data-Based Insights About Merck & Co Inc
Stocks Register· 7 days agoMerck & Co Inc (NYSE:MRK) price on Thursday, May 09, rose 0.08% above its previous day’s close as an upside momentum from buyers pushed the stock’s value ...
Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations
FierceBiotech· 3 days agoMerck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...
Top Stock Reports for Broadcom, Merck & Airbnb
Zacks via Yahoo Finance· 12 hours agoToday's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Merck & Co., Inc. (MRK) and Airbnb, Inc. (ABNB).
Tri-Cities doctor fined after prescribing ivermectin for COVID. 2nd physician charged
Tri-City Herald McClatchy via AOL· 5 days agoOne doctor joined in a lawsuit against the Washington Medical Commission with the help of the Silent...
...Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment - ...
Benzinga· 3 days agoMonday, Merck & Co Inc MRK announced the discontinuation of the vibostolimab and pembrolizumab...
Merck cancels trial of melanoma treatment due to immune-mediated adverse events
Clinical Trials Arena via Yahoo Finance· 2 days agoUS pharmaceutical company Merck & Co Inc (MSD) has discontinued a Phase III trial investigating a...
Merck's (NYSE:MRK) investors will be pleased with their notable 90% return over the last three years
Simply Wall St. via Yahoo Finance· 6 days agoBy buying an index fund, investors can approximate the average market return. But if you pick the...
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Zacks· 7 days agoFree Report) is one of the stocks most watched by Zacks.com visitors lately. Shares of this pharmaceutical company have returned +2.2% over the past month versus the Zacks S&P 500 composite's ...